HumaScan delays BreastAlert launch

Article

Developmental-stage company HumaScan has hit a roadblock in its quest to commercialize a nonimaging screening device for breast cancer that could compete with mammography. The company anticipates a four to six-month delay for its BreastAlert Differential

Developmental-stage company HumaScan has hit a roadblock in its quest to commercialize a nonimaging screening device for breast cancer that could compete with mammography. The company anticipates a four to six-month delay for its BreastAlert Differential Temperature Sensor (DTS), a noninvasive, adjunctive screening device for breast disease.

BreastAlert DTS detects temperature differences between breasts, which may indicate the presence of breast disease, including breast cancer, according to the Cranford, NJ-based company.

The initial introduction of BreastAlert DTS was scheduled to begin in the New York metropolitan area on June 30, but was pushed back to make manufacturing refinements the company believes are necessary to achieve consistent, high-quality production. HumaScan anticipates proceeding with its planned national launch in the fourth quarter of 1997.

HumaScan has approximately $11 million in cash and equivalents on hand, and with monthly expenditures of about $325,000, the company believes that it has more than enough capital on hand to successfully launch BreastAlert DTS.

Medical supply company Physicians Sales and Service, which signed an exclusive supply and distribution agreement with HumaScan in February 1996, appears to be supporting HumaScan's decision to delay the launch of BreastAlert DTS. PSS chairman Patrick Kelly said that PSS remains committed to the exclusive distribution of BreastAlert DTS.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.